Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

3.095 +0.185 (+6.36%)
Streaming Delayed Price Updated: 10:51 AM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks Gaining Momentum
The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power. 
Via MarketBeat
News headline image
Editas Medicine's Return On Capital Employed Insights ↗
  
Via Benzinga
News headline image
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Editas Medicine: Q2 Earnings Insights ↗
  Editas Medicine (NASDAQ:EDIT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
BMO Initiates Coverage On This Gene Editing Spearhead ↗
 
Via Benzinga
News headline image
Expert Ratings for Editas Medicine ↗
Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
The 3 Leaders of the Gene Editing Revolution ↗
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
News headline image
7 Moonshot Investments Upending a $10 Trillion Industry ↗
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
News headline image
Editas Medicine: Q1 Earnings Insights ↗
Editas Medicine (NASDAQ:EDIT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Good morning! We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
News headline image
16 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares rose 38% to $1.27 in pre-market trading following a Form 4 filing showing the purchase of 2,044,676 shares by CEO Salvatore Palella at an average price of... 
Via Benzinga
News headline image
Cathie Wood Is Selling Gene Editing Stocks. Here’s Why. ↗
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves? 
Via InvestorPlace
News headline image
Editas Medicine's Return On Capital Employed Insights ↗
Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter. 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Editas Medicine Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗
Editas Medicine (NASDAQ:EDIT) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Editas Medicine (EDIT) Conference Call Follow this link to... 
Via Benzinga
News headline image
Editas Medicine's EDIT-301 receives FDA Rare Pediatric Disease designation for Beta Thalassemia ↗
The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassemia from leading... 
Via Benzinga
News headline image
Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents ↗
The U.S. Patent and Trademark Office has ruled in favor of the Broad Institute of MIT and Harvard in a dispute over the patents around CRISPR gene-editing technology. The... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
News headline image
27 Stocks Moving in Monday's Pre-Market Session ↗
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 123.4% to $0.76 in pre-market trading after jumping 36% on Monday. American Rebel Holdings, Inc. (NASDAQ: AREB) rose 28.6... 
Via Benzinga
News headline image
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test ↗
Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein. 
Via Investor's Business Daily
News headline image
Expert Ratings For Editas Medicine ↗
Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.